Voclosporin

CHEMBL5314379 Phase 4 معتمد Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1214.6 g/mol

LogP

7.9

Phase

4

Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

الوزن الجزيئي

1214,6000 g/mol

LogP

7,90

TPSA

279,00 Å²

قاعدة ليبينسكي للخمسة

راسب

المجالات العلاجية

Psoriasis Systemic Lupus Erythematosus

Pharmacokinetics (PK)

Pharmacodynamics (PD)

البنية ثنائية الأبعاد

SVG PNG

Cite this structure

Embed this structure

SMILES

C=C/C=C/C[C@@H](C)[C@@H](O)[C@H]1C(=O)N[C@@H](CC)C(=O)N(C)CC(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@H](C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](CC(C)C)C(=O)N(C)[C@@H](C(C)C)C(=O)N1C

InChI

InChI=1S/C63H111N11O12/c1-25-27-28-29-41(15)53(76)52-57(80)66-44(26-2)59(82)68(18)34-49(75)69(19)45(30-35(3)4)56(79)67-50(39(11)12)62(85)70(20)46(31-36(5)6)55(78)64-42(16)54(77)65-43(17)58(81)71(21)47(32-37(7)8)60(83)72(22)48(33-38(9)10)61(84)73(23)51(40(13)14)63(86)74(52)24/h25,27-28,35-48,50-53,76H,1,26,29-34H2,2-24H3,(H,64,78)(H,65,77)(H,66,80)(H,67,79)/b28-27+/t41-,42+,43-,44+,45+,46+,47+,48+,50+,51+,52+,53-/m1/s1

Molecular Formula

C63H111N11O12

HBD / HBA

5 / 12

الروابط القابلة للدوران

16

الذرات الثقيلة

86

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

الأسئلة الشائعة

Voclosporin is a novel calcineurin inhibitor structurally related to cyclosporine that suppresses T-cell activation by blocking calcineurin-mediated dephosphorylation of NFAT transcription factors, thereby reducing IL-2 production and T-cell proliferation in immune-mediated diseases. It is approved for the treatment of adult patients with active lupus nephritis in combination with immunosuppressive background therapy. Compared to cyclosporine, voclosporin has a more predictable pharmacokinetic profile and additional podocyte-stabilizing effects.

Yes, Voclosporin is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314379. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 6918486. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

هل تبحث عن معلومات ملائمة للمرضى؟

Voclosporin على PillFYI

البنية

بيانات سريعة

الصيغة الجزيئية: C63H111N11O12
المرادفات: 1

روابط خارجية

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

إخلاء المسؤولية الطبية

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.